RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Docetaxel at Beginning of Androgen Deprivation Therapy Boosts Overall Survival by over 1 Year
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 14
SP 12
OP 13
DO 10.1177/155989771414004
UL http://mdc.sagepub.com/content/14/14/12.abstract
AB This article discusses the results of the Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer trial [CHAARTED; NCT00309985]. The trial demonstrated that the use of docetaxel at the beginning of androgen deprivation therapy (ADT) increases overall survival (OS) in patients with metastatic prostate cancer by >1 year compared with ADT alone.